MapLight Therapeutics, Inc. (MPLT) Cash Flow Statement
MapLight Therapeutics, Inc. (MPLT) generated -$174.7M of operating cash flow over the twelve months to 2026-06-30, spent $453000 on capital expenditure and had free cash flow of -$175.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MPLTMapLight Therapeutics, Inc.Follow MPLT — free
—
Price chart with a free account
- Market cap
- 369.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 1 Dec, in 38 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -78.8 | -138.1 | -174.7 | |
| Capital expenditure | 0.8 | 0.5 | -0.5 | |
| Free cash flow | -79.6 | -138.6 | -175.1 | |
| Dividends paid | — | 0.0 | — | |
| Stock-based compensation | 1.1 | 36.0 | — |
USD millions · SEC XBRL
MapLight Therapeutics, Inc. — questions
- What is MapLight Therapeutics, Inc.'s operating cash flow?
- -$174.7M over the twelve months to 2026-06-30.
- How much does MapLight Therapeutics, Inc. spend on capital expenditure?
- $453000 over the twelve months to 2026-06-30.
- What is MapLight Therapeutics, Inc.'s free cash flow?
- -$175.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from MapLight Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.